 Intermittent concurrent regimens zidovudine dideoxycytidine murine immunodeficiency model murine retrovirus-induced immunodeficiency model efficacy intermittent regimens zidovudine AZT dideoxycytidine ddC continuous concurrent therapy Intermittent oral AZT therapy effective mice virus continuous oral AZT therapy Continuous oral ddC therapy mg/kg/day survival time average weeks untreated mice weekly AZT ddC therapy survival time weeks effective therapy additive synergistic Concurrent AZT ddC therapy effective continuous AZT therapy model increase survival time